《新股消息》沛嘉醫療(09996.HK)超購1,183倍成今年凍資王 一手中籤率僅8.5%
內地介入手術醫療器械生產商沛嘉醫療(09996.HK)公布招股結果,公開發售錄得超額認購逾1,183.41倍,凍資約2,800億元,成為今年凍資王。啟動重新分配及回撥後,公開發售股份數目佔全球發售初步可供認購股份總數約50%。每手1,000股,中籤率僅8.5%。該股將於明日(5月15日)掛牌。摩根士丹利及華泰國際為聯席保薦人。
每股定價15.36元,集資淨額22億,當中約65%將用作開發及商業化公司的核心產品TaurusOne以及其他主要在研產品;約10%將用於為其他在研產品正在進行的臨床試驗、準備註冊備案及潛在商業化推出提供資金;8%用於加強研發能力以豐富產品管線;10%將用於潛在戰略收購、投資、合作夥伴及許可機會;以及7%為營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.